RxDoctor Payments Data

Ali Valimahomed, MD

Interventional Pain Medicine · Holmdel, NJNPI 1760807184

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $271,998 of the $414,756 with a category attached, or 65.6%. 46 manufacturers reported payments, led by SPR Therapeutics, Inc at 41.0% of the total. Among interventional pain medicine clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$414,756in general payments, 2019–2025

Across 1,117 payments — averaging $371.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SPR Therapeutics, Inc$170K
  • Nalu Medical, Inc.$134K
  • Biotronik NRO, Inc.$28K
  • Boston Scientific$23K
  • Medtronic$16K
  • Vertos Medical, Inc.$14K
  • plus $30K from 40 others
$448,718in research payments, 2019–2025

Across 11 payments — averaging $40,793 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Nalu Medical, Inc.$373K
  • SPR Therapeutics, Inc$76K

What the payments were for

  • Consulting fees$271,99866%
  • Speaking & faculty fees$40,55010%
  • Grants$9070%
  • Travel & lodging$54,37013%
  • Food & beverage$46,58311%
  • Entertainment$3470%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$414,756 in reported general payments places this provider in the 95th percentile of 82 interventional pain medicine providers in New Jersey.

See all interventional pain medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$499,974
Medicare patients
520
Services billed
4,859

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MovantikNaloxegol Oxalate11$4,401
Gabapentin428$4,151
Lidocaine31$3,727
Buprenorphine35$3,052
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen88$1,669
Pregabalin83$1,340
Tizanidine Hcl153$1,152
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen72$950
Tramadol Hcl184$886
Metaxalone11$806
Naloxone Hcl14$713
Hydromorphone Hcl41$647
Morphine Sulfate ErMorphine Sulfate17$556
Etodolac11$524
Oxycodone Hcl44$521

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Holmdel

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →